HOOKIPA Pharma Inc.

OTCPK:HOOK Stock Report

Market Cap: US$15.2m

HOOKIPA Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Malte Peters

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage16.88%
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Analysis Article • Dec 21

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

Unfortunately for some shareholders, the HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) share price has dived 26% in the last...
Analysis Article • Nov 19

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 27

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shareholders that were waiting for something to happen have been dealt a blow with...
Analysis Article • Aug 13

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

To the annoyance of some shareholders, HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares are down a considerable 29% in the...
Analysis Article • Jun 22

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares have had a horrible month, losing 34% after a relatively good period...
Analysis Article • Apr 28

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares have continued their recent momentum with a 25% gain in the last month...
Analysis Article • Mar 24

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

The analysts covering HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) delivered a dose of negativity to shareholders today, by...
Analysis Article • Aug 11

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...
Analysis Article • May 16

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...
Analysis Article • Apr 26

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Nov 19

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Shareholders in HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) may be thrilled to learn that the analysts have just delivered a...
Seeking Alpha • Jul 25

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Clinical-stage biotech HOOKIPA Pharma (NASDAQ:HOOK) announced on Monday that the FDA accepted its Investigational New Drug (IND) application for HB-300, an experimental therapy for metastatic castration-resistant prostate cancer. A Phase 1/2 trial for the treatment is expected to start by early next year. “FDA acceptance of our IND application for HB-300 is a key milestone as we expand and diversify our oncology pipeline and arenavirus platform from viral antigens to self-antigens,” Chief Executive Joern Aldag remarked. HB-300 is identified as an arenaviral immunotherapy designed to target two well-established antigens of prostate cancer, PAP and PSA.  Parallelly, HOOKIPA (HOOK) announced that the FDA accepted the Drug Master File (DMF) to support the future submission of data specific to its replicating arenavirus platform. With the concurrent acceptance of DMF, “we have reduced cycle time between completion of preclinical studies and clinical entry of our pipeline projects,” Aldag added. Read: In April, HOOKIPA (HOOK) announced pre-clinical data supporting the potential of its arenaviral platform against various cancers.

CEO Compensation Analysis

How has Malte Peters's remuneration changed compared to HOOKIPA Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$73m

Dec 31 2024US$2mUS$281k

-US$44m

Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$232kn/a

-US$82m

Compensation vs Market: Malte's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD627.70K).

Compensation vs Earnings: Malte's compensation has increased whilst the company is unprofitable.

CEO

Malte Peters (63 yo)

1.8yrs
Tenure
US$1,666,767
Compensation

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Leadership Team

NamePositionTenureCompensationOwnership
Malte Peters
CEO, President & Director1.8yrsUS$1.67mno data
Mary Coelho
Executive VP1.8yrsUS$1.08m0.17%
$ 25.2k
Daniel Pinschewer
Co-Founder & Member of Scientific Advisory Board15.3yrsno datano data
Mark Winderlich
Chief Research & Development Officer2.1yrsno datano data
2.0yrs
Average Tenure
56yo
Average Age

Experienced Management: HOOK's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Malte Peters
CEO, President & Director3.3yrsUS$1.67mno data
Mary Coelho
Executive VP3.1yrsUS$1.08m0.17%
$ 25.2k
Daniel Pinschewer
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Paul-Henri Lambert
Member of Scientific Advisory Boardno dataUS$46.34kno data
Sean Cassidy
Independent Director1.8yrsUS$79.53k0%
$ 0
Igor Matushansky
Chairman of the Scientific Advisory Boardno dataUS$1.42mno data
Julie O'Neill
Independent Non-Executive Chair7.5yrsUS$89.99k0.0039%
$ 585.8
David Kaufman
Independent Director7.1yrsUS$81.32k0.0036%
$ 538.7
3.3yrs
Average Tenure
57yo
Average Age

Experienced Board: HOOK's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 23:18
End of Day Share Price 2026/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HOOKIPA Pharma Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Swayampakula RamakanthH.C. Wainwright & Co.
Debjit ChattopadhyayH.C. Wainwright & Co.